scholarly journals Direct-acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens

2019 ◽  
Vol 2 (3) ◽  
pp. e106 ◽  
Author(s):  
Hidenori Toyoda
PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0233446
Author(s):  
Dung Thanh Nguyen ◽  
Thanh Thi Thanh Tran ◽  
Ngoc My Nghiem ◽  
Phuong Thanh Le ◽  
Quang Minh Vo ◽  
...  

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Mohamed Hussein Abdelwahab ◽  
Shereen Abou Bakr Saleh ◽  
Ghada Abdelrahman Ahmed ◽  
Asmaa Mady Gomaa Mady

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.


2003 ◽  
Vol 38 ◽  
pp. 147-148
Author(s):  
W. Jessner ◽  
M. Gschwantler ◽  
E. Formann ◽  
P. Steindl-Munda ◽  
H. Hofmann ◽  
...  

2002 ◽  
Vol 36 ◽  
pp. 113 ◽  
Author(s):  
Wolfgang Jessner ◽  
Michael Gschwantler ◽  
Thomas Watkins-Riedel ◽  
Petra Steindl-Munda ◽  
Christian Mueller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document